APRIL 17, 2024
Extended patent protection for OX640 in the US
Key News
April 2, 2024
Conditions for early redemption of existing bond fulfilled
MARCH 28, 2024
Annual and Sustainability Report 2023
Read all documents related to the refinancing of the existing bond - MARCH 2024
A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
Development pipeline targeting large medical needs
AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products